Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Phase II/III Trial of First Line Platinum/Etoposide With or Without Atezolizumab (NSC#783608) in Patients With Advanced or Metastatic Poorly Differentiated Extrapulmonary Neuroendocrine Carcinomas (NEC)

NCT05058651 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT05058651
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05058651 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Phase II/III Trial of First Line Platinum/Etoposide With or Without Atezolizumab (NSC#783608) in Patients With Advanced or Metastatic Poorly Differentiated Extrapulmonary Neuroendocrine Carcinomas (NEC)
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2/3
Overall status
Recruiting
Start date
June 28, 2022
Completion date
October 1, 2028
Enrollment
189 (estimated)
Sites
263

Conditions

As the registry lists them; a condition with its own page is linked.

advanced extrapulmonary neuroendocrine carcinoma, metastatic extrapulmonary neuroendocrine carcinoma, recurrent extrapulmonary neuroendocrine carcinoma, unresectable extrapulmonary neuroendocrine carcinoma